254 related articles for article (PubMed ID: 30237154)
21. Testicular invading refractory multiple myeloma during bortezomib treatment successfully treated with lenalidomide: a case report.
Miyao K; Sakemura R; Sakai T; Tsushita N; Kato T; Niimi K; Ono Y; Sawa M
Ann Hematol; 2014 Mar; 93(3):529-30. PubMed ID: 23820941
[No Abstract] [Full Text] [Related]
22. Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
Vogl DT; Stadtmauer EA; Richardson PG; Sonneveld P; Schuster MW; Irwin D; Facon T; Harousseau JL; Boral A; Neuwirth R; Anderson KC
Br J Haematol; 2009 Nov; 147(4):531-4. PubMed ID: 19725827
[TBL] [Abstract][Full Text] [Related]
23. Long-term remission of acquired von Willebrand syndrome associated with multiple myeloma using bortezomib and dexamethasone therapy.
Katagiri S; Akahane D; Amano K; Ohyashiki K
Haemophilia; 2016 Nov; 22(6):e557-e559. PubMed ID: 27641423
[No Abstract] [Full Text] [Related]
24. The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma.
Hashimoto S; Kuroha T; Yano T; Sato N; Furukawa T
Intern Med; 2016; 55(20):3025-3028. PubMed ID: 27746443
[TBL] [Abstract][Full Text] [Related]
25. Impact of novel agents followed by autologous hematopoietic stem cell transplantation for multiple myeloma patients aged 65 years or older: a retrospective single Institutional analysis.
Minoia C; Pisapia G; Palazzo G; Ingrosso C; Buonanno M; Spinosa C; Prudenzano A; Pricolo G; Mazza P
Bone Marrow Transplant; 2015 Nov; 50(11):1486. PubMed ID: 26281030
[No Abstract] [Full Text] [Related]
26. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
[TBL] [Abstract][Full Text] [Related]
27. [Proteasome inhibitors].
Alexandre J
Rev Med Interne; 2005 Oct; 26(10):812-5. PubMed ID: 16129520
[TBL] [Abstract][Full Text] [Related]
28. [Role of novel proteasome inhibitors in the treatment of relapsed/refractory multiple myeloma].
Ri M
Rinsho Ketsueki; 2018; 59(10):2162-2168. PubMed ID: 30305522
[TBL] [Abstract][Full Text] [Related]
29. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
[TBL] [Abstract][Full Text] [Related]
30. [Not Available].
Hitz F
Praxis (Bern 1994); 2016; 105(21):1255-1260. PubMed ID: 28573955
[No Abstract] [Full Text] [Related]
31. Enhancing ER stress in myeloma.
Wallington-Beddoe CT; Pitson SM
Aging (Albany NY); 2017 Jul; 9(7):1645-1646. PubMed ID: 28758893
[No Abstract] [Full Text] [Related]
32. Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma.
Mu S; Kuroda Y; Shibayama H; Hino M; Tajima T; Corrado C; Lin R; Waldron E; Binlich F; Suzuki K
Eur J Clin Pharmacol; 2016 Feb; 72(2):153-61. PubMed ID: 26494130
[TBL] [Abstract][Full Text] [Related]
33. Ixazomib in the management of relapsed multiple myeloma.
Touzeau C; Moreau P
Future Oncol; 2018 Aug; 14(20):2013-2020. PubMed ID: 29469592
[TBL] [Abstract][Full Text] [Related]
34. The aspartyl protease DDI2 drives adaptation to proteasome inhibition in multiple myeloma.
Op M; Ribeiro ST; Chavarria C; De Gassart A; Zaffalon L; Martinon F
Cell Death Dis; 2022 May; 13(5):475. PubMed ID: 35589686
[TBL] [Abstract][Full Text] [Related]
35. A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.
Waterman GN; Yellin O; Swift RA; Mapes R; Eades B; Ackerman E; Berenson JR
Ann Hematol; 2011 Feb; 90(2):193-200. PubMed ID: 20809423
[TBL] [Abstract][Full Text] [Related]
36. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
[TBL] [Abstract][Full Text] [Related]
37. Safety of proteasome inhibitors for treatment of multiple myeloma.
Schlafer D; Shah KS; Panjic EH; Lonial S
Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
[TBL] [Abstract][Full Text] [Related]
38. Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma.
Bai Y; Su X
Asia Pac J Clin Oncol; 2021 Feb; 17(1):29-35. PubMed ID: 32920949
[TBL] [Abstract][Full Text] [Related]
39. A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus - clinical significance and possible mechanisms: a case report.
Takemori N; Imai G; Hoshino K; Ooi A; Kojima M
J Med Case Rep; 2018 Feb; 12(1):40. PubMed ID: 29454372
[TBL] [Abstract][Full Text] [Related]
40. Successful treatment with enasidenib, bortezomib, and dexamethasone for the synchronous occurrence of IDH2-positive acute myeloid leukemia and multiple myeloma.
Moore DC; Nelson V; Muslimani A
Ann Hematol; 2021 Dec; 100(12):3053-3055. PubMed ID: 33001279
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]